Genetic and Metabolic Disease: Diagnosis, Outcomes, and Treatment
Nov
12
2023
Room 302
-
Hynes Convention Center
4:30
- 6:00 PM EST
Description
Abstracts
- ARBM-101 AS A SAFE AND POTENT THERAPEUTIC OPTION FOR WILSON DISEASE
- DECREASED PREGNANE X RECEPTOR (PXR) EXPRESSION PROMOTES LIVER NODULE DEVELOPMENT IN Atp7b-/- MICE
- METABOLIC SYNDROME ASSOCIATED FATTY LIVER DISEASE IS A SIGNIFICANT RISK FACTOR FOR THE DEVELOPMENT OF HEPATIC EVENTS IN ALPHA-1-ANTITRYPSIN PI*ZZ INDIVIDUALS.
- EVALUATION OF NON-CERULOPLASMIN COPPER BY PROTEIN SPECIATION (NCC-SP) AND 24-HOUR URINARY COPPER EXCRETION (UCE) FOR MONITORING CHELATOR TREATMENT IN PATIENTS WITH WILSON DISEASE.
- SERUM Z POLYMER LEVELS AND FACTORS AFFECTING INCREASED LIVER FIBROSIS ARE ASSOCIATED WITH FUTURE SEVERE LIVER DISEASE OUTCOMES IN A PROSPECTIVE COHORT OF ADULTS WITH ALPHA-1-ANTITRYPSIN DEFICIENCY .